Marcus Schmidt
- Oncology top 0.2%
- HER2/EGFR in Cancer Research 76
- Cancer Treatment and Pharmacology 50
- Cancer Immunotherapy and Biomarkers 25
- Cancer Cells and Metastasis 25
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies 90
- Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies 63
- Genetics top 1%
- Estrogen and related hormone effects 16
- Biochemistry top 2%
-
- Ovarian cancer diagnosis and treatment 17
- Co-authors
- Jan G. HengstlerMathias GehrmannJohannes EttlTamás PintérKatalin BoérIgor BondarenkoDennis J. SlamonXin Huang
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Marcus Schmidt
284 papers receiving 8.8k citations
Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 5.0k
- Cancer Research 2.7k
- Pulmonary and Respiratory Medicine 2.8k
- Genetics 612
- Biochemistry 265
Countries citing papers authored by Marcus Schmidt
This map shows the geographic impact of Marcus Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus Schmidt more than expected).
Fields of papers citing papers by Marcus Schmidt
This network shows the impact of papers produced by Marcus Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus Schmidt. The network helps show where Marcus Schmidt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Marcus Schmidt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 6 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 2 | |
| 6 | 2023 | 20 | |
| 7 | 2023 | 0 | |
| 8 | 2023 | 1 | |
| 9 | 2022 | 60 | |
| 10 | 2021 | 6 | |
| 11 | 2020 | 14 | |
| 12 | Update der S3-Leitlinie Mammakarzinom: Was gibt es Neues für Pathologen? | 2019 | 1 |
| 13 | First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. | 2016 | 10 |
| 14 | Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptor-positive Breast Cancer. | 2015 | 16 |
| 15 | 2015 | 4 | |
| 16 | 2010 | 108 | |
| 17 | New prognostic and predictive factors in breast cancer. | 2010 | 6 |
| 18 | 2009 | 28 | |
| 19 | The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancerbreakdown → | 2008 | 588 |
| 20 | 2008 | 69 |
About Marcus Schmidt
Marcus Schmidt is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine and Obstetrics and Gynecology, having authored 297 papers that have together received 9.0k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (90 papers), HER2/EGFR in Cancer Research (76 papers), Advanced Breast Cancer Therapies (63 papers), Cancer Treatment and Pharmacology (50 papers), Cancer Immunotherapy and Biomarkers (25 papers), Cancer Cells and Metastasis (25 papers), Ovarian cancer diagnosis and treatment (17 papers) and Estrogen and related hormone effects (16 papers). The work is most often cited by research in Oncology (5.0k citations), Cancer Research (2.7k citations), Pulmonary and Respiratory Medicine (2.8k citations), Genetics (612 citations) and Biochemistry (265 citations). Marcus Schmidt has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Jan G. Hengstler, Mathias Gehrmann, Johannes Ettl, Tamás Pintér, Katalin Boér, Igor Bondarenko, Dennis J. Slamon, Xin Huang, Richard S. Finn and Ravindranath Patel. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Care, Breast Cancer Research and Treatment and Journal of Cancer Research and Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.